Compare SPRU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRU | ATNM |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | 159 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 42.0M |
| IPO Year | 2019 | 2013 |
| Metric | SPRU | ATNM |
|---|---|---|
| Price | $2.82 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 48.2K | ★ 207.0K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | 14.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,194,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.68 | 11.11 |
| 52 Week Low | $1.13 | $0.95 |
| 52 Week High | $6.75 | $1.95 |
| Indicator | SPRU | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 43.40 |
| Support Level | $2.51 | $0.99 |
| Resistance Level | $3.32 | $1.25 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 10.57 | 14.81 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.